MSD announces third-quarter 2026 financial results and raises full-year outlook
Total sales reached $18.1 billion with strong oncology growth. The company also highlighted key pipeline milestones and updated its full-year 2026 earnings guidance.
Latest MSD News & Updates
See the latest news and media coverage for MSD. We track all announcements, press releases, and industry mentions in real time, all in one place.
Research-driven biopharmaceutical and animal health company
msd.com- Headquarters
- Rahway, United States
- Company type
- Public company
- Number of employees
- 39,000+
- Industry
- Pharmaceuticals
Last updated
Latest news about MSD
In short: MSD posted 5% Q2 sales growth, won Keytruda approvals, and advanced oncology, immunology and HIV pipelines.
Company announcements
MSD presents one-year BRUNELLO study results for remigromig
Remigromig demonstrated non-inferior visual acuity versus ranibizumab in diabetic macular edema but showed higher rates of proliferative diabetic retinopathy and discontinuation due to adverse events.
MSD shares positive Phase 2b data for HS treatment
The investigational anti-TL1A monoclonal antibody targets moderate to severe hidradenitis suppurativa, marking a first for anti-TL1A biologics in dermatology.
MSD announces second-quarter 2026 financial results and regulatory milestones
Total sales rose 5% to $16.6 billion, driven by oncology growth. The company also highlights FDA approvals for LIPFENDRA and KEYTRUDA combinations.
Media coverage
Merck & Co., Inc. Q3 Earnings Call Highlights
Merck & Co., Inc. (NYSE:MRK) reported third-quarter 2026 revenue of $18.1 billion, up 5% from a year earlier, as growth in oncology, vaccines,...
Merck Boosts FY26 Outlook - Update
While reporting financial results for the third quarter on Thursday, biopharmaceutical company Merck & Co., Inc. (MRK), known as MSD outside the U.S. and Canada...
KEYTRUDA® (pembrolizumab) as Monotherapy Reduced the Risk of Dis
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first...
MSD presents positive results of sacituzumab tirumotecan in patients with endometrial cancer
MADRID, Oct 27 (EUROPA PRESS) - MSD has announced positive results from the pivotal phase 3 'TroFuse-005' trial, which evaluates sacituzumab tirumotecan (sac-TMT...
Never miss news about MSD
Track MSD and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
MSD competitors & trending companies
Browse news for competitors to MSD and other trending companies.